A Phase 3, double-masked, randomized, multi-center, placebo-controlled, parallel-group, 4-week study evaluating the efficacy and safety of 0.02% STN1013900 ophthalmic solution compared to its vehicle under concomitant use of Latanoprost ophthalmic solution 0.005% in subjects with primary open angle glaucoma or ocular hypertension

Sakamoto Kayoko0 个研究点目标入组 234 人开始时间: 2021年5月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•20 years of age or older
•Diagnosis of POAG or OHT in both eyes
•Best-corrected visual acuity (BCVA) +0.7 log MAR or better (>= 20/100 Snellen or >= 0.20 in decimal unit) in each eye
•Willingness and ability to give signed informed consent and follow study instructions

•Ophthalmic:
•Clinically significant ocular disease
•Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles
•Previous glaucoma intraocular surgery
•Refractive surgery in either eye
•Ocular trauma
•Ocular infection
•Any corneal disease
•Known hypersensitivity to any component of the study drugs, or to topical anesthetic
•Clinically significant systemic disease
•Participation in any investigational study within 30 days prior to screening
•Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

发起方

Sakamoto Kayoko